                         SEQUENCE LISTING

<110>  Intra-ImmuSG Private Limited
 
<120>  Vaccine and/or antibody for viral infection

<130>  008109217

<150>  PCT/SG2021/050197
<151>  2021-04-08

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  419
<212>  PRT
<213>  SARS-CoV2

<400>  1

Met Ser Asp Asn Gly Pro Gln Asn Gln Arg Asn Ala Pro Arg Ile Thr 
1               5                   10                  15      


Phe Gly Gly Pro Ser Asp Ser Thr Gly Ser Asn Gln Asn Gly Glu Arg 
            20                  25                  30          


Ser Gly Ala Arg Ser Lys Gln Arg Arg Pro Gln Gly Leu Pro Asn Asn 
        35                  40                  45              


Thr Ala Ser Trp Phe Thr Ala Leu Thr Gln His Gly Lys Glu Asp Leu 
    50                  55                  60                  


Lys Phe Pro Arg Gly Gln Gly Val Pro Ile Asn Thr Asn Ser Ser Pro 
65                  70                  75                  80  


Asp Asp Gln Ile Gly Tyr Tyr Arg Arg Ala Thr Arg Arg Ile Arg Gly 
                85                  90                  95      


Gly Asp Gly Lys Met Lys Asp Leu Ser Pro Arg Trp Tyr Phe Tyr Tyr 
            100                 105                 110         


Leu Gly Thr Gly Pro Glu Ala Gly Leu Pro Tyr Gly Ala Asn Lys Asp 
        115                 120                 125             


Gly Ile Ile Trp Val Ala Thr Glu Gly Ala Leu Asn Thr Pro Lys Asp 
    130                 135                 140                 


His Ile Gly Thr Arg Asn Pro Ala Asn Asn Ala Ala Ile Val Leu Gln 
145                 150                 155                 160 


Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu Gly Ser 
                165                 170                 175     


Arg Gly Gly Ser Gln Ala Ser Ser Arg Ser Ser Ser Arg Ser Arg Asn 
            180                 185                 190         


Ser Ser Arg Asn Ser Thr Pro Gly Ser Ser Arg Gly Thr Ser Pro Ala 
        195                 200                 205             


Arg Met Ala Gly Asn Gly Gly Asp Ala Ala Leu Ala Leu Leu Leu Leu 
    210                 215                 220                 


Asp Arg Leu Asn Gln Leu Glu Ser Lys Met Ser Gly Lys Gly Gln Gln 
225                 230                 235                 240 


Gln Gln Gly Gln Thr Val Thr Lys Lys Ser Ala Ala Glu Ala Ser Lys 
                245                 250                 255     


Lys Pro Arg Gln Lys Arg Thr Ala Thr Lys Ala Tyr Asn Val Thr Gln 
            260                 265                 270         


Ala Phe Gly Arg Arg Gly Pro Glu Gln Thr Gln Gly Asn Phe Gly Asp 
        275                 280                 285             


Gln Glu Leu Ile Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln Ile 
    290                 295                 300                 


Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg Ile 
305                 310                 315                 320 


Gly Met Glu Val Thr Pro Ser Gly Thr Trp Leu Thr Tyr Thr Gly Ala 
                325                 330                 335     


Ile Lys Leu Asp Asp Lys Asp Pro Asn Phe Lys Asp Gln Val Ile Leu 
            340                 345                 350         


Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu Pro 
        355                 360                 365             


Lys Lys Asp Lys Lys Lys Lys Ala Asp Glu Thr Gln Ala Leu Pro Gln 
    370                 375                 380                 


Arg Gln Lys Lys Gln Gln Thr Val Thr Leu Leu Pro Ala Ala Asp Leu 
385                 390                 395                 400 


Asp Asp Phe Ser Lys Gln Leu Gln Gln Ser Met Ser Ser Ala Asp Ser 
                405                 410                 415     


Thr Gln Ala 
            


<210>  2
<211>  31
<212>  PRT
<213>  Artificial

<220>
<223>  Peptide fragment Peptide#1

<400>  2

Cys Ile Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln Ile Ala Gln 
1               5                   10                  15      


Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg Ile Gly 
            20                  25                  30      


<210>  3
<211>  31
<212>  PRT
<213>  Artificial

<220>
<223>  Peptide fragement Peptide#2

<400>  3

Cys Ile Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser 
1               5                   10                  15      


Arg Ile Gly Met Glu Val Thr Pro Ser Gly Thr Trp Leu Thr Tyr 
            20                  25                  30      


<210>  4
<211>  31
<212>  PRT
<213>  Artificial

<220>
<223>  Peptide fragment Peptide#3

<400>  4

Cys Val Ile Leu Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro 
1               5                   10                  15      


Pro Thr Glu Pro Lys Lys Asp Lys Lys Lys Lys Ala Asp Glu Thr 
            20                  25                  30      


<210>  5
<211>  141
<212>  PRT
<213>  Artificial

<220>
<223>  Heavy chain comprising signal peptide

<400>  5

Met Asp Trp Leu Trp Asn Leu Leu Phe Leu Met Ala Ala Ala Gln Ser 
1               5                   10                  15      


Ala Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys 
            20                  25                  30          


Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu 
    50                  55                  60                  


Lys Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala 
65                  70                  75                  80  


Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser 
                85                  90                  95      


Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Lys 
            100                 105                 110         


Tyr Phe Cys Thr Arg Pro Leu Tyr Tyr Asp Tyr Asp Gly His Ala Met 
        115                 120                 125             


Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
    130                 135                 140     


<210>  6
<211>  122
<212>  PRT
<213>  Artificial

<220>
<223>  Heavy chain variable region

<400>  6

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Lys Tyr Phe Cys 
                85                  90                  95      


Thr Arg Pro Leu Tyr Tyr Asp Tyr Asp Gly His Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120         


<210>  7
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  VH CDR1 sequence

<400>  7

Asn Tyr Gly Met Asn 
1               5   


<210>  8
<211>  17
<212>  PRT
<213>  Artificial

<220>
<223>  VH CDR2 sequence

<400>  8

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  9
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  VH CDR3 sequence

<400>  9

Pro Leu Tyr Tyr Asp Tyr Asp Gly His Ala Met Asp Tyr 
1               5                   10              


<210>  10
<211>  423
<212>  DNA
<213>  Artificial

<220>
<223>  Heavy chain nucleotide sequence comprising signal peptide 
       sequence

<400>  10
atggattggc tgtggaactt gctattcctg atggcagctg cccaaagtgc ccaagcacag       60

atccagttgg tgcagtctgg acctgagctg aagaagcctg gagagacagt caagatctcc      120

tgcaaggctt ctgggtatac cttcacaaac tatggaatga actgggtgaa gcaggctcca      180

ggaaagggtt taaagtggat gggctggata aacacctaca ctggagagcc aacatatgct      240

gatgacttca agggacggtt tgccttctct ttggaaacct ctgccagtac tgcctatttg      300

cagatcaaca acctcaaaaa tgaggacatg gctaaatatt tctgtacaag acccctctac      360

tatgattacg acggccatgc tatggactac tggggtcaag gaacctcagt caccgtctcc      420

tca                                                                    423


<210>  11
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR1 sequence

<400>  11

Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr 
1               5                   10                  


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR2 sequence

<400>  12

Gln Met Ser Asn Leu Ala Ser 
1               5           


<210>  13
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR3 sequence

<400>  13

Gln Asn Leu Glu Leu Met Trp Thr 
1               5               


<210>  14
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain variable region

<400>  14

Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Thr 
1               5                   10                  15      


Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn 
            20                  25                  30          


Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro 
        35                  40                  45              


Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Ser Ser Gly Ser Thr Asp Phe Thr Leu Arg Ile Ser Arg 
65                  70                  75                  80  


Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu 
                85                  90                  95      


Leu Met Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110 


